 Home > Medical News > Latest Medical News > Sanofi and Baidu collaborate to develop mRNA vaccines and partner with Owkin to deploy AI pharmaceuticals

Sanofi and Baidu collaborate to develop mRNA vaccines and partner with Owkin to deploy AI pharmaceuticals

 Last Update: 2022-01-14
 Source: Internet
 Author: User

Tags

used 20

industrial hand soap

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Article source: Medical Rubik's Cube Info

Author: Sunshine

Recently, Sanofi reached two collaborations to develop new therapies for 4 specific types of cancers (non-small cell lung cancer, triple-negative breast cancer, mesothelioma, and multiple myeloma) with Owkin; obtained Baidu mRNA sequence design Algorithm (LinearDesign technology) for the design of vaccines and therapeutic products

Cooperate with Baidu to develop mRNA vaccine

On November 22, Baidu announced that it had licensed the LinearDesign technology to Sanofi, France, for the design of vaccines and therapeutic products

According to the agreement, Baidu licenses Sanofi to use its mRNA sequence design algorithm LinearDesign technology for mRNA vaccine and drug development

LinearDesign uses a dynamic programming algorithm to design the most stable COVID-19 vaccine sequence within 10 minutes, while optimizing sequence stability and protein expression to improve vaccine effectiveness

It is worth noting that on October 11 this year, Baidu and Si Microbiology used the new algorithm LinearDesign to optimize the new crown mRNA vaccine sequence research has been published in the preprint journal arXiv

With the outbreak of the new crown epidemic, vaccine giant Sanofi lags behind BioNTech/Pfizer and Moderna in the development of new crown mRNA vaccines

Hand in hand with Owkin to lay out AI pharmacy

On November 18, Sanofi announced that it has reached a cooperation with AI and precision medicine company Owkin to develop new therapies for 4 specific types of cancer (non-small cell lung cancer, triple negative breast cancer, mesothelioma, and multiple myeloma) , While establishing a powerful disease model

According to the terms of the agreement, Sanofi will make a US$180 million equity investment in Owkin and pay US$90 million within 3 years.

Owkin was established in 2016.

In order to protect privacy and accelerate medical research with AI, Owkin has established a global research network driven by joint learning, which allows data scientists to securely connect decentralized multi-party data and build AI models without the need to aggregate data

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.